## SC029 FIRST YEAR RENAL OUTCOME OF TRANSPLANTATIONS OF KIDNEYS FROM HEPATITIS C INFECTED DONORS TO HEPATITIS C NEGATIVE RECIPIENTS

Miklos Zsolt Molnar<sup>1,2</sup>, Manish Talwar<sup>1,2</sup>, Vasanthi Balaraman<sup>1,2</sup>, Anshul Bhalla<sup>1,2</sup>, Ambreen Azhar<sup>1,2</sup>, Masahiko Yazawa<sup>1,2,3</sup>, Makoto Tsujita<sup>1,2,4</sup>, Pradeep Podila<sup>5</sup>, Satheesh Nair<sup>1,2</sup>, James Eason<sup>1,2</sup>

<sup>1</sup>Methodist University Hospital, James D Eason Transplant Institute, Memphis, United States of America, <sup>2</sup>University of Tennessee Health Science Center, Surgery, Memphis, United States of America, <sup>3</sup>St. Marianna University School of Medicine, Divison of Nephrology and Hypertension, Japan, <sup>4</sup>Nagoya Daini Red Cross Hospital, Division of Nephrology and Hypertension, Japan and <sup>5</sup>Methodist Le Bonheur Healthcare, Memphis, United States of America

**Background and Aims:** Transplant centers in US are increasingly willing to transplant kidneys from hepatitis C infected donors to hepatitis C negative recipients. Long-term renal outcome data from non-prophylactic treatment approach outside clinical trials is missing.

**Method:** We compared kidney graft function of 132 hepatitis C negative recipients, who received HCV infected (NAT+ and antibody+/-; HCV+) versus HCV negative (NAT- and antibody-; HCV-) in 2018, in a single center, retrospective, observational study. Categorical variables were compared using  $\chi^2$  tests and continuous variables were compared using t-tests or Mann–Whitney U-tests, as appropriate. Linear regression was applied to assess independent association between graft function and HCV viremic status.

**Results:** The mean±SD age of recipients was 52±11 years, 44% were female, 20% and 79% of recipients were Caucasian and African-American, respectively. Baseline characteristics were similar between HCV+ vs HCV- groups, except dialysis duration, donors race, KDPI and cold ischemic time (Table). The DGF rate, estimated GFRs at post-transplant 3, 6, 9 and 12 months was similar between HCV+ and HCV- groups (Table). HCV viremic status was not a predictor of 3, 6, 9 and 12 months eGFR in our unadjusted model and after adjustment for donor and recipient characteristics.

**Conclusion:** Recipients of HCV-viremic kidneys have similar renal allograft function in the first year after transplantation compared to those who received from HCV-non-viremic kidneys.

## Table:

iii34 | Abstracts

Parameter	Entire cohort	HCV+	HCV-	P- value		
Observations (n)	132	73	59			
Recipient baseline characteristics						
Age (years), mean (SD)	52 (11)	52 (11)	52 (12)	0.86		
Female gender, N,	58 (44%)	30 (41%)	28 (47%)	0.46		
(%)						
<u>Race, N, (%)</u> Caucasian	27 (2004)	14 (1004)	12 (2204)	0.62		
African American	27 (20%)	14 (19%)	13 (22%)	0.62		
	104 (79%)	58 (80%)	46 (78%)			
Other Diskuis duration	1 (1%)	1 (1%)	0 (0%)	<0.01		
Dialysis duration	60 (37-87)	49 (30-75)	71 (50-98)	<0.01		
(months), median						
(IQR)						
<u>Comorbidity, N, (%)</u> Diabetes	61 (46%)	36 (49%)	25 (42%)	0.43		
			23 (42%) 57 (97%)	0.45		
Hypertension	128 (97%)	71 (97%)	. ,			
Peripheral vascular disease	9 (7%)	8 (11%)	1 (2%)	0.04		
Coronary artery	21 (16%)	11 (15%)	10 (17%)	0.74		
disease						
Chronic obstructive	8 (6%)	5 (7%)	3 (5%)	0.67		
pulmonary disease						
Donor Characteristics						
Age (years), mean (SD)	33 (10)	32 (5)	34 (13)	0.17		
Female gender, N,	60 (45%)	37 (47%)	26 (44%)	0.77		
(%)	00 (1070)	37 (1773)	20 (1170)	5.77		
DCD, N, (%)	18 (14%)	8 (11%)	10 (17%)	0.32		
Comorbidity, N, (%)						

Continued

Continued				
Parameter	Entire cohort	HCV+	HCV-	P-
Diabetes	2 (2%)	1 (1%)	1 (2%)	<b>value</b> 0.88
Hypertension	2 (2%) 12 (9%)	6 (8%)	6 (10%)	0.88
Race, N, (%)	12 (970)	0 (070)	0(10%)	0.70
Caucasian	107 (82%)	70 (96%)	37 (64%)	<0.01
	. ,	· ,	. ,	<0.01
	. ,	. ,	. ,	<0.01
		50(10)	30 (21)	<0.01
,		102 (162	152 (01	<0.01
	,		,	<0.01
	<i>,</i>		,	0.25
	4.9 (0.9)	4.0 (0.0)	5.0 (1.5)	0.25
	13 (10%)	6 (8%)	7 (12%)	0.40
,	13 (1070)	0 (070)	7 (1270)	0.42
	63 (19)	63 (17)	64 (21)	0.76
	05(15)	05 (17)	01(21)	0.70
	66 (19)	66 (17)	66 (21)	0.97
	00(1))	00(17)	00 (21)	0.57
· · · ·	66 (17)	66 (15)	67 (20)	0.61
	00(17)	00 (10)	0, (20)	0.01
1				
	65 (19)	65 (16)	66 (22)	0.65
months after trans-				
African American Other KDPI, mean (SD) <i>Transplant characteristic</i> Cold Ischemic Time (hours), median (IQR) ATG dose (mg/kg), mean (SD) <i>Renal Outcome Data</i> Delayed Graft Function, N, (%) Estimated GFR at 3 months after trans- plantation (ml/min), mean (SD) Estimated GFR at 6 months after trans- plantation (ml/min), mean (SD) Estimated GFR at 9 months after trans- plantation (ml/min), mean (SD) Estimated GFR at 12 months after trans- plantation (ml/min), mean (SD)	21 (16%) 3 (2%) 45 (19) 5 18.2 (12.7- 21.8) 4.9 (0.9) 13 (10%) 63 (19) 66 (19) 66 (17) 65 (19)	0 (0%) 3 (4%) 50 (16) 19.3 (16.2- 23.2) 4.8 (0.8) 6 (8%) 63 (17) 66 (17) 66 (15) 65 (16)	21 (36%) 0 (0%) 38 (21) 15.3 (9.1- 20.3) 5.0 (1.3) 7 (12%) 64 (21) 66 (21) 67 (20) 66 (22)	<0.01 <0.01 0.25 0.49 0.76 0.97 0.61